Menu

Danaher Corporation (DHR)

$221.13
+12.74 (6.11%)
Market Cap

$158.3B

P/E Ratio

46.4

Div Yield

0.56%

52W Range

$174.06 - $272.72

Company Profile

At a glance

Resilient Portfolio & Operational Edge: Danaher's transformation into a focused life sciences and diagnostics innovator, underpinned by the Danaher Business System (DBS), provides a durable business model with over 80% recurring revenue, enabling superior operational efficiency and cost management even amidst macro headwinds.

Bioprocessing and Diagnostics Lead Growth: Strong performance in the Biotechnology segment, particularly bioprocessing (high single-digit core growth expected for FY25), and robust non-respiratory growth in Diagnostics (double-digits for Cepheid's core assays) are key drivers, offsetting softness in Life Sciences and China.

Strategic Innovation & Technology Moat: Continuous investment in differentiated technologies like the Xcellerex X-platform bioreactor, XenoTOF 8600 mass spectrometry, and AI-powered digital pathology enhances competitive advantages, drives higher yields, reduces costs, and accelerates drug/diagnostic development.

Price Chart

Loading chart...

The most compelling investment themes are the ones nobody is talking about yet.

Every Monday, get three under-the-radar themes with catalysts, data, and stocks poised to benefit.

Sign up now to receive them!

Also explore our analysis on 5,000+ stocks